Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

With -w, grep will match “error” but skip things like “errors” or “terror.” The difference can be subtle, but when you’re trying to be precise, it matters a lot. I use this when I’m searching through ...

Bowen Yang is leaving “Saturday Night Live” after this weekend’s Christmas show, in the middle of Season 51. “He has been there for seven years — time to move on,” said a person familiar with Yang’s ...

Nvidia's restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...